Official Title
Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip
Brief Summary

This is a two-arm, randomized, open label, monocenter, controlled study to evaluate the safety and efficacy of Viusid plus Asbrip in patients with mild and moderate symptoms of respiratory illness caused by Coronavirus 2019 infection.

Detailed Description

This is a two-arm, randomized, open label, monocenter, controlled study to evaluate the

safety and efficacy of Viusid plus Asbrip in patients with mild and moderate symptoms of

respiratory illness caused by Coronavirus 2019 infection.



A total of 80 subjects will be randomized 2:1 in this study. 50 patients will be assigned to

receive daily oral doses of 4,5 g of Viusid every 12 hours and 10 ml of Asbrip every 8 hours

and standard care with antivirals or not. Other 30 patients will be assigned to receive only

standard care.



Treatment duration: 21 days



Objective of the study: to increase the effectiveness of therapy for patients with Covid-19

using food supplements Viusid and Asbrip.



Research objectives:



1. To assess the clinical symptoms of Covid-19 in patients on the background of combination

therapy with the inclusion of food supplements Viusid + Asbrip.



2. To investigate the dynamics of indicators of laboratory diagnostics against the

background of complex therapy with the inclusion of food additives Viusid + Asbrip in

the complex treatment of Covid -19.



3. To study the dynamics of indicators of instrumental methods of treatment.



4. To develop an algorithm for the management of patients with coronavirus infection in

order to increase the effectiveness of therapy and rehabilitation of patients with this

pathology.

Active, not recruiting
COVID19
COVID-19 Pneumonia
COVID-19 Respiratory Infection
Viral Infection
Respiratory Tract Infections
Infection, Coronavirus
SARS-CoV2 Infection

Dietary Supplement: Viusid and Asbrip
Patients will be assigned to receive daily oral doses of 4.5gr of Viusid and 10 ml of Asbrip every 8 hours and standard care.
Viusid Plus Asbrip Adjuvant
Viusid Plus Asbrip Monotherapy

Drug: COVID-19 Standard Therapy
Patients will be assigned to receive the standard therapy for COVID-19 disease: Antibiotic, Antivirals, Analgaesic, Anti-inflammatory drugs.
Control
Viusid Plus Asbrip Adjuvant

Eligibility Criteria

Inclusion Criteria: 1. Male or female adult aged ≥18 years at the time of enrollment. 2. Subjects with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection as defined below: Mild (uncomplicated) Illness: - Diagnosed with COVID-19 by a standardized RT-PCR assay and - Mild symptoms, such as fever, rhinorrhea, mild cough, sore throat, malaise, headache, muscle pain, or malaise, but with no shortness of breath and - No signs of a more serious lower airway disease and - RR12) 5. Subjects requiring Renal Replacement Therapy (RRT) at the time of screening 6. History of uncontrolled diabetes 7. History of severe chronic kidney disease or requiring dialysis 8. Any uncontrolled active systemic infection requiring admission to an intensive care unit (ICU); Note: Subjects infected with chronic hepatitis B virus or hepatitis C virus will be eligible for the study if they have no signs of hepatic decompensation. 9. Patients with malignant tumor, or other serious systemic diseases

10. Patients who are participating in other clinical trials

11. Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Viusid or Asbrip are not eligible; and

12. Inability to provide informed consent or to comply with test requirements

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Countries
Kazakhstan
NCT Number
Keywords
Covid-19
supportive care
Immuno-modulator
Antiviral
symptoms relieve
MeSH Terms
Infection
Communicable Diseases
Respiratory Tract Infections
Coronavirus Infections
Virus Diseases